Corium’s Adlarity (donepezil transdermal system) Receives the US FDA’s Approval for the Treatment of Alzheimer Disease
Shots:
- The US FDA has approved Adlarity (5/10mg/day formulations, qw) for the treatment of AD. Additionally, patients may be switched from 5 or 10mg/day donepezil directly to Adlarity & the therapy is expected to be available in early 2022
- The new formulation of the therapy is delivered directly into a patient’s skin and bypasses the digestive system skin reducing the likelihood of adverse GI events associated with donepezil. The therapy has been developed using Corium's CORPLEX transdermal technology
- The therapy has the potential to substantially benefit patients, caregivers, and healthcare providers & provides effective, well-tolerated & stable dosing for 7 days who are unable to take oral donepezil
Ref: PR Newswire | Image: LinkedIn
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
